Researchers at the Kennedy Institute, Oxford, have made a groundbreaking discovery by mapping the cellular dynamics in patients treated with anti-tumor necrosis factor (anti-TNF), a common therapy for autoimmune diseases like inflammatory bowel disease (IBD). Using single-cell RNA sequencing to analyze gut samples from patients before and after treatment, they created the largest cell atlas of IBD. Their findings explain why anti-TNF is effective for some patients but not others, addressing a major challenge in IBD treatment. This insight could lead to the development of new, more personalized therapies. The research was published in Nature Immunology.
1 Like